Asset Details
Do you wish to reserve the book?
Targeting BCL‐xL in Myeloid Malignancies: From Inhibitors to PROTAC
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting BCL‐xL in Myeloid Malignancies: From Inhibitors to PROTAC
Do you wish to request the book?
Targeting BCL‐xL in Myeloid Malignancies: From Inhibitors to PROTAC
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting BCL‐xL in Myeloid Malignancies: From Inhibitors to PROTAC
2026
Overview
Restoring apoptosis in malignant cells represents a central goal of anticancer therapy. Tumour cells often escape cell death by overexpressing anti‐apoptotic members of the BCL‐2 protein family, particularly BCL‐2, BCL‐xL, and MCL1. These proteins inhibit the intrinsic mitochondrial apoptotic pathway through intricate interactions with pro‐apoptotic partners and direct modulation of the mitochondrial outer membrane. Their pivotal role in cell survival has established them as attractive therapeutic targets. Over the past two decades, significant efforts have been devoted to developing selective small‐molecule inhibitors capable of neutralising these proteins and reactivating apoptosis. A first milestone was the discovery of ABT‐263 (navitoclax), a dual BCL‐2/BCL‐xL inhibitor. Building on this achievement, the development of venetoclax, a highly selective BCL‐2 inhibitor, marked a major breakthrough, demonstrating potent pro‐apoptotic activity and clinical efficacy in several leukaemia subtypes. Despite these advances, the design of inhibitors of BCL‐2 family members remains challenging, largely due to the structural characteristics of the BH3‐binding groove, which is both shallow and hydrophobic, complicating the identification of molecules with optimal binding affinity and selectivity. PROTACs targeting BCL‐xL may represent a promising future strategy, potentially overcoming the intrinsic limitations of small molecule inhibitors.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ bcl-X Protein - antagonists & inhibitors
/ BCL‐2
/ BCL‐xL
/ Genes
/ Humans
/ Leukemia
/ Lymphoma
/ PROTAC
/ Proteins
/ Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors
/ Proto-Oncogene Proteins c-bcl-2 - metabolism
/ Review
/ Sulfonamides - therapeutic use
/ Tumors
